Jean Paul Atallah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jean Paul Atallah has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Uroosa Ibrahim
Department of Hematology-Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
2 shared publications - Ahmed Mostafa Gad
The Department of Plastic, Burn and Maxillofacial Surgery, Faculty of Medicine, Ain Shams University
1 shared publication - Bader Alshamsan
Department of Medicine, College of Medicine, Qassim University, Buraydah 52571, Saudi Arabia
1 shared publication - Bassel Nazha
Department of Hematology and Medical Oncology Emory University School of Medicine Atlanta Georgia USA
1 shared publication Elias Moussaly
Department of Medicine, Staten Island University Hospital, New York, NY
1 shared publication- Elias Moussaly
Staten Island University Hospital, Staten Island, NY
1 shared publication
Latest Publications
- Open Access
- 5 April 2022
- Published by Wiley in Journal of Oncology
- Vol. 2022, 1-9
Capecitabine Monotherapy as Palliative Treatment for Patients with Recurrent/Metastatic Nasopharyngeal Cancer
Background. Numerous chemotherapeutic agents have antitumor activity in recurrent/metastatic (R/M) nasopharyngeal cancer (NPC). Evidence of capecitabine’s effectiveness as monotherapy is limited. Capecitabine tolerability in solid malignancies has ethnic and geographical variability. We investigated capecitabine’s tolerability and identified potential prognostic factors for clinical outcomes in R/M NPC. Methods. A consecutive retrospective cohort of patients who received capecitabine as the first recurrence, second- or third-line monotherapy for metastatic NPC (2011–2019) was reviewed concerning patient characteristics, pathological features, treatment outcomes, and toxicity. Results. Fifty-one patients were eligible (median age at diagnosis: 42 [35.5–52.5] years). Most patients (78.4%) tolerated a standard oral dose of 1,250 mg/m2 capecitabine (2 weeks on/1 week off) in a 3-week cycle. The objective response rate was 49%, and the disease control rate was 66.7%, with a median response duration of 6.2 months. Hand-foot syndrome (HFS) was associated with a higher objective response rate (odds ratio, 5.1 [95% confidence interval: 1.18–21.98]; ). The median follow-up duration was 17.8 (interquartile range: 7.8–30.4) months. The median (95% confidence interval) progression-free survival and overall survival were 6.6 (4.3–8.8) and 32.7 (25.9–39.5) months, respectively. HFS ( ), better performance status ( ), and absence of brain metastasis ( ) were associated with prolonged progression-free survival. Conclusion. Capecitabine monotherapy is effective and well-tolerated as a palliative treatment for R/M NPC. Despite the lower incidence of HFS in our patients, it remained a favorable prognostic factor for objective response and progression-free survival.
- 5 April 2022
- Published by Wiley in Journal of Oncology
- Vol. 2022, 1-9
Open AccessCapecitabine Monotherapy as Palliative Treatment for Patients with Recurrent/Metastatic Nasopharyngeal Cancer
Background. Numerous chemotherapeutic agents have antitumor activity in recurrent/metastatic (R/M) nasopharyngeal cancer (NPC). Evidence of capecitabine’s effectiveness as monotherapy is limited. Capecitabine tolerability in solid malignancies has ethnic and geographical variability. We investigated capecitabine’s tolerability and identified potential prognostic factors for clinical outcomes in R/M NPC. Methods. A consecutive retrospective cohort of patients who received capecitabine as the first recurrence, second- or third-line monotherapy for metastatic NPC (2011–2019) was reviewed concerning patient characteristics, pathological features, treatment outcomes, and toxicity. Results. Fifty-one patients were eligible (median age at diagnosis: 42 [35.5–52.5] years). Most patients (78.4%) tolerated a standard oral dose of 1,250 mg/m2 capecitabine (2 weeks on/1 week off) in a 3-week cycle. The objective response rate was 49%, and the disease control rate was 66.7%, with a median response duration of 6.2 months. Hand-foot syndrome (HFS) was associated with a higher objective response rate (odds ratio, 5.1 [95% confidence interval: 1.18–21.98]; ). The median follow-up duration was 17.8 (interquartile range: 7.8–30.4) months. The median (95% confidence interval) progression-free survival and overall survival were 6.6 (4.3–8.8) and 32.7 (25.9–39.5) months, respectively. HFS ( ), better performance status ( ), and absence of brain metastasis ( ) were associated with prolonged progression-free survival. Conclusion. Capecitabine monotherapy is effective and well-tolerated as a palliative treatment for R/M NPC. Despite the lower incidence of HFS in our patients, it remained a favorable prognostic factor for objective response and progression-free survival.
- Open Access
- 23 October 2017
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 26 (12) , 1317-1319
Investigational PD-1 inhibitors for advanced non-small lung cancer: new players in a shifting paradigm
(2017). Investigational PD-1 inhibitors for advanced non-small lung cancer: new players in a shifting paradigm. Expert Opinion on Investigational Drugs: Vol. 26, No. 12, pp. 1317-1319.
- 23 October 2017
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 26 (12) , 1317-1319
Open AccessInvestigational PD-1 inhibitors for advanced non-small lung cancer: new players in a shifting paradigm
(2017). Investigational PD-1 inhibitors for advanced non-small lung cancer: new players in a shifting paradigm. Expert Opinion on Investigational Drugs: Vol. 26, No. 12, pp. 1317-1319.
- Open Access
- 1 September 2016
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 68 (3) , A17-A20
Quiz Page September 2016
- 1 September 2016
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 68 (3) , A17-A20
Open AccessQuiz Page September 2016
- Open Access
- 1 January 2015
- Published by Elmer Press, Inc. in World Journal of Oncology
- Vol. 6 (5) , 459-463
Primary Non-Hodgkin’s Lymphoma of the Spine: A Case Report and Literature Review
Primary Non-Hodgkin’s Lymphoma of the Spine: A Case Report and Literature Review
- 1 January 2015
- Published by Elmer Press, Inc. in World Journal of Oncology
- Vol. 6 (5) , 459-463
Open AccessPrimary Non-Hodgkin’s Lymphoma of the Spine: A Case Report and Literature Review
Primary Non-Hodgkin’s Lymphoma of the Spine: A Case Report and Literature Review